Sanofi MS Drug Doesn’t Benefit Patients, U.S. Panel Says

Sanofi’s Lemtrada hasn’t proven to help against disability in the treatment of relapsing multiple sclerosis, said U.S. advisers who questioned whether the company’s studies were conducted well enough to assess the drug.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.